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Summary. Background: Patients with severe hemophilia A who have been treated extensively with factor VIII products have a low but potentially serious risk of inhibitor development. It is unknown why these patients develop inhibitors, and data on product-related immunogenicity are scarce. Aims: To summarize the currently available evidence on the relationship between inhibitor development and recombinant FVIII product type in previously treated patients (PTPs) with severe hemophilia A. Methods: Longitudinal studies were included that reported on de novo inhibitor formation in patients with baseline FVIII activity levels of < 0.02 IU mL À1 who had been treated with FVIII for at least 50 days. Pooled incidence rates of inhibitor development according to product types were calculated with a random intercept Poisson regression model. Results: Forty-one independent cohorts were included; 39 patients developed de novo inhibitors during 19 157 person-years of observation. The overall incidence rate was 2.06 per 1000 person-years, with a 95% confidence interval (CI) of 1.06-4.01. According to product type, the pooled incidence rates were 0.99 (95% CI 0. These results suggest that some products may be associated with increased immunogenicity. However, the low incidence of inhibitors in PTPs and
Introduction
The development of factor VIII-specific neutralizing antibodies (inhibitors) remains the most important treatment complication in patients with congenital hemophilia A. Inhibitor development is associated with increased morbidity and mortality [1] [2] [3] , and occurs primarily during the first 50 days of treatment with FVIII [4, 5] after a median of 14.5 days of exposure to FVIII (interquartile range 9.75-20.0) [6] . Patients who have been treated with FVIII for > 50 days, also termed previously treated patients (PTPs), are relatively tolerant to FVIII, and inhibitor development is rare [7] , with a reported rate of 2.14 per 1000 person-years [8] . It has been suggested that inhibitor incidence follows a bimodal distribution, and that, in older people, the risk of developing inhibitors increases again [9] .
Knowledge about the immunogenicity of recombinant FVIII (rFVIII) products in PTPs is scarce, which is largely attributable to the rarity of inhibitor development during this phase of replacement therapy. In addition, findings of different inhibitor rates among rFVIII products in PTPs might seem conflicting [7, 10] . The observed differences in immunogenicity between rFVIII products may be explained by product characteristics such as the specific amino acid sequence, culture conditions, stabilizing agents, and/or post-translational modifications [11] .
Two previous meta-analyses have assessed productrelated immunogenicity in previously treated hemophilia A patients [7, 10] . Several new studies have been published since the latest review (published in 2013), which is one of the reasons for performing a new meta-analysis. Moreover, a new meta-analysis is needed with methods that can appropriately handle rare event situations and differences in follow-up time among included studies.
The objective of this systematic review and meta-analysis was to quantify and compare the current knowledge on incidence rates of inhibitor formation according to rFVIII product type among PTPs affected with severe or moderately severe hemophilia A.
Methods
A systematic literature review was performed to identify studies that assessed de novo inhibitor development in PTPs with severe or moderately severe hemophilia A who were treated exclusively with one brand of rFVIII. The Meta-analysis of Observational Studies in Epidemiology (MOOSE) [12] and Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) [13] guidelines were followed.
Inclusion/exclusion criteria
Types of study All longitudinal studies that assessed de novo inhibitor development and that reported total, mean or median follow-up time in person-years were eligible. Original articles, letters published in peer-reviewed journals and meeting abstracts were eligible for inclusion. There was no restriction on date of publication or language. We excluded case-control studies, case series, crosssectional studies, studies with a follow-up time of < 3 months, studies with < 10 patients, studies in which treatment for surgery was the main goal, pharmacokinetic studies, and studies with duplicate data. The authors of studies in which inhibitor incidence rates were not reported separately for PTPs were asked to provide these data. If these data were not provided, these studies were excluded.
Types of patient All patients with severe or moderately severe hemophilia A (baseline FVIII activity of < 0.02 IU mL
À1
) with at least 50 days of prior exposure to FVIII were eligible. Furthermore, only patients who were exclusively treated with one brand of rFVIII during the observation period were eligible. Studies that also included patients with < 50 days of exposure to FVIII were only included when separate results were available for the subset of patients with > 50 days of exposure to FVIII.
Types of rFVIII product rFVIII product type (analyzed according to brand) was the determinant in the primary analysis. Finally, rFVIII products were also categorized according to generation: first-generation products (human/animal proteins in production and final formulation), second-generation products (human/animal proteins in production but not in final formulation), third-generation products (no human/animal proteins used in production or final formulation), and fourth-generation products (no human/ animal proteins used in production or final formulation, and human embryonic kidney cells used as the cell line). Studies performed with extended half-life rFVIII products were excluded, mainly because there were not enough studies performed with these products.
Types of endpoint The primary endpoint was de novo inhibitor development defined as the first occurrence of an inhibitor according to the cut-off used by the investigators of the original studies. The secondary outcome was high-titer de novo inhibitor formation, defined as a peak inhibitor titer of at least 5 Bethesda Units mL À1 .
experienced librarian (J. W. Schoones, Walaeus Library, Leiden University Medical Center, Leiden, the Netherlands). The initial search was performed in February 2016. Additional studies were included by searching monthly in PubMed up to November 2017 (search terms are reported in Fig. S1 ).
Study selection and data extraction
Two reviewers (S. Hassan and A. Cannav o) independently scanned all titles and abstracts to select articles for further scrutiny. Full-text versions of each selected article were reviewed to assess eligibility. Inclusion of an article was determined by consensus between the two reviewers. Consultation with a third reviewer (J. G. van der Bom) was carried out in cases of disagreement. To avoid multiple counting of patients included in more than one study, recruitment periods and catchment areas were recorded, and, if needed, authors were contacted for clarification. Data were extracted independently by two investigators (S. Hassan and A. Cannav o). A structured electronic data extraction form was used. When the required data were missing, the original investigator(s) were contacted for further information.
Quality assessment
The methodological quality of each article was assessed by use of the Downs and Black checklist [14] . For the non-comparative studies in our systematic review, only items relevant to this study design were scored (18 of the 27 items from the original checklist [14] ). The modified Downs and Black checklist contained eight items about reporting accuracy, three items about external validity, six items about internal validity, and one item about study power. Eight items that were only applicable to comparative studies (i.e. all items about randomization, blinding, concealment of treatment allocation, and confounding) and one item about the use of P-values were removed. The wording of some questions was modified to provide clearer scoring criteria to improve consistency among raters (Table S2) . Each item could be scored as 'no' or 'unknown', which yielded 0 points, or 'yes', which yielded 1 point. The overall score was derived by adding up each item score; each study could score 0-18 points. Two reviewers (A. Cannav o and S. Hassan) evaluated each article independently, and a third reviewer (J. G. van der Bom) was consulted if there was any discrepancy.
Data analysis
Statistical analysis The total inhibitor incidence rate and high-titer inhibitor incidence rate in PTPs were estimated for each study as the number of de novo inhibitors divided by the number of person-years on a given rFVIII product. Conventional random-effects meta-analysis methods (such as the DerSimonian-Laird random-effects method) are biased when the outcome of interest is rare, and also when continuity corrections are applied [15] . Therefore, we pooled the incidence rates of the individual studies and calculated the pooled incidence rate ratio (IRR) of inhibitor development according to product type by using a random intercept Poisson regression model [16] . Heterogeneity was explored by estimating the between-study variance (s 2 ) and by visually assessing the extent to which the confidence intervals (CIs) of the individual studies overlapped. As the most frequently used product, Advate was used as the reference category in the analysis according to product type.
Sensitivity analysis To verify whether the results were robust to changes in methodology, two sensitivity analyses were conducted. In the first sensitivity analysis, we restricted the main analysis to studies that reported information only for patients with severe disease (baseline FVIII activity of < 0.01 IU mL
À1
). In the second sensitivity analysis, we restricted the main analysis to large studies (i.e. studies with > 150 person-years of follow-up).
Summary of findings
The main results of the product comparisons (including an overall quality assessment) are also summarized in a 'summary of findings' table (Table 3) , according to the GRADE approach [17] .
Results

Included studies
A flowchart of the literature search is shown in Fig. 1 , and the search terms are shown in Fig. S1 . In total, 1605 articles were screened on their title and abstract. Eightytwo unique articles were reviewed in full; of these, 52 articles were excluded. Thirty articles were selected for the analysis, and four additional articles [48] [49] [50] [51] were included after monthly searches on PubMed. Most articles reported on a single cohort of patients using one brand of rFVIII product, whereas three articles [23, 25, 26] provided information on multiple cohorts. Fischer et al.
[23] reported on five cohorts using different rFVIII products, Recht et al. [26] reported on two cohorts with slightly different inclusion criteria, and Hay et al. [25] reported on three cohorts using different rFVIII products. In total, 34 articles reporting on 41 cohorts were included . The characteristics of the 52 excluded articles are shown in Table S1 , and references to the 52 excluded articles (labeled S1-S52) are also shown in Table S1 . Eighteen articles did not separately report inhibitor incidence and follow-up time for PTPs with severe or moderate disease (but were otherwise eligible for inclusion). The corresponding authors were contacted but did not provide additional data. Consequently, these 18 articles were excluded from the meta-analysis (Table S1) .
Study characteristics
Overall, 39 patients developed inhibitors during 19 157 person-years of observation (Table 1) . One study did not provide information on the total number of patients [23] , so the overall number of patients included in this meta-analysis is unknown. Seven studies evaluated Advate (6043 person-years, six inhibitors), four studies evaluated Kogenate or Helixate (537 person-years, five inhibitors), 10 studies evaluated Kogenate FS/Bayer or Helixate FS/NexGen (7386 person-years, 10 inhibitors), three studies evaluated Refacto (609 person-years, seven inhibitors), and four studies (containing five cohorts) evaluated Refacto AF (3226 person-years, 10 inhibitors).
Furthermore, one study evaluated GreenGene F (56 person-years, one inhibitor), three studies evaluated Kovaltry/Iblias (165 person-years, no inhibitors), three studies evaluated NovoEight (551 person-years, no • Surgical studies (n = 9)
• PK studies (n = 8)
• < 10 patients (n = 4)
• Full results were published inhibitors), three studies evaluated Nuwiq (85 personyears, n o inhibitors), and two studies evaluated Recombinate (499 person-years, no inhibitors). Because of the small sample sizes, studies evaluating GreenGene F, Kovaltry/Iblias, NovoEight, Nuwiq and Recombinate were included for calculation of the overall incidence rate, but were excluded from product-specific analyses. In total, 12 studies were excluded (1356 person-years, one inhibitor). We found similar methodological quality across studies with the modified Downs and Black checklist (median score, 11; range, 6-16), except for two studies with a high risk of bias that were published as a letter to the editor [18] (score, 6) and a conference poster [19] (score, 8) (Table S2 ). The majority of studies were similar in quality, so we did not perform a sensitivity analysis based on methodological quality.
Risk of inhibitor formation according to recombinant rFVIII product
Overall incidence rate and incidence rate per rFVIII product The overall inhibitor incidence rate among previously treated patients was 2.06 per 1000 person-years, with a 95% CI of 1.06-4.01. The incidence rates of inhibitor formation were 0.99 (95% CI 0. 37 (Table 2) . As compared with full-length rFVIII, the pooled IRR for B-domain-deleted rFVIII was 4.80 (95% CI 1.32-17.40). As compared with rFVIII products derived from CHO cells, the pooled IRR was 0.62 (95% CI 0.17-2.34) for rFVIII products derived from BHK cells. As compared with second-generation rFVIII products, the pooled IRRs were 2.54 (95% CI 0.45-14.27) for first-generation rFVIII products and 0.75 (95% CI 0.21-2.66) for third-generation rFVIII products (Table 2) .
Sensitivity analysis
The sensitivity analyses showed that the results for each rFVIII brand varied significantly with changes to methodology (Tables S4 and S5 ). However, this can be partly explained by the low number of studies per brand. Furthermore, the results of the sensitivity analyses were approximately in line with the results of *Possible overlap with the EUHASS registry [21] . †Patient recruitment period not reported; unclear whether there is any overlap with the EUHASS registry [21] .
the main analysis with regard to the overall incidence rate and when rFVIII products were analyzed according to length, cell line, and generation. Nevertheless, this shows that that the most important results of the main analysis are not very robust to changes in methodology (Tables S4  and S5 ). 
Discussion
This meta-analysis comprehensively reviews published reports of rFVIII products in relation to immunogenicity among PTPs with hemophilia. In total, 34 studies reporting on 41 cohorts were included, with 39 inhibitor events and 19 157 person-years of observation. The incidence rate among PTPs was 2.06 per 1000 person-years (95% CI 1.06-4.01). Formal comparisons of products showed a statistically significantly higher incidence of inhibitors among patients using Kogenate/Helixate and Refacto than among those using Advate, but not than among those using Kogenate FS/Helixate NexGen or Refacto AF. Taken as a whole, B-domain-deleted rFVIII products were associated with an increased risk of inhibitor formation as compared with full-length rFVIII products. However, the overall quality of evidence was low, mainly because of the high risk of bias and confounding, the lack of power to detect an effect in most studies (given the rare outcome), and the lack of consistency among studies evaluating the same rFVIII product. Therefore, the aforementioned results have to be interpreted with caution (Table 3) .
Comparison with previous reviews
The overall incidence of inhibitors in PTPs in our study corroborates earlier findings [8, [52] [53] [54] [55] . Recently, two previous systematic reviews have evaluated the association between rFVIII product type and inhibitor formation in PTPs [7, 10] .
In 2011, the first of the two meta-analyses was published; its focus was mainly on the risk of inhibitor formation with B-domain-deleted rFVIII products as compared with full-length rFVIII products [10] . This meta-analysis included prospective studies of patients who had been treated for > 50 days at baseline. A mixedeffects Cox proportional hazards model with study as a random effect was used to pool and compare studies. Owing to incomplete reporting, individual follow-up time was estimated for most non-inhibitor patients. Fourteen of 29 studies in the previous meta-analysis were also included in our current meta-analysis. The following nine studies were included in the previous meta-analysis but excluded from the current meta-analysis: three surgical studies (S7, S27, and S28), one case series (S2), two studies that did not adequately report prior exposure to FVIII (S49 and S51), and three studies that did not adequately report follow-up time (S39, S41, and S46) (see Table S1 for references of excluded studies). Similarly to our study, this meta-analysis found a statistically significantly higher risk of inhibitor formation in PTPs using B-domaindeleted rFVIII than among PTPs using full-length rFVIII (hazard ratio 7.26, 95% CI 2.12-24.9).
A more recent meta-analysis from 2013 did not report any differences in immunogenicity [7] . Thirteen of 33 studies in this previous meta-analysis were also included in the current meta-analysis. The following 11 studies were included in the previous meta-analysis but excluded from the current meta-analysis: three surgical studies (S7, S27, and S28), three studies that did not report hemophilia severity and/or prior days of exposure to FVIII (S43, S49, and S9), four studies that did not report follow-up time (S40, S41, S46, and S47), and one study in which the FVIII brand used was not specified (S10) (see Table S1 for references of excluded studies). The method of Laird and Mosteller was used to pool study results. Crude proportions of inhibitor development for each FVIII product were indirectly compared by evaluating whether statistically significant between-group heterogeneity existed according to Cochran's Q-statistic. The crude proportions of inhibitor development were 1.0% (95% CI 0.5-1.8%) for Advate, 2.6% (95% CI 1.6-4.4%) for Kogenate (first generation), and 1.9% (95% CI 1.1-3.4%) for Refacto (first generation). No statistically significant Q-statistic was found on the basis of the type of FVIII concentrate (Q-statistic = 6.854, P = 0.077); this was confirmed by a univariate meta-regression analysis (these results were not shown). Cochran's Q-statistic, however, is not a sensitive tool for assessing heterogeneity, as it has low power to detect heterogeneity if the event rate is very low [56] , and hence this meta-analysis indicated, at most, the absence of gross differences by product.
In this meta-analysis, Kogenate/Helixate and Kogenate FS/Helixate NexGen were categorized and analyzed as one product group, complicating comparisons between individual rFVIII products. Furthermore, only information on the cumulative incidence of inhibitor formation (i.e. the numbers of events per person) per product was provided, without correction for study follow-up time. It we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty (⨁⨁⨁◯): we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty (⨁⨁◯◯): our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. Very low certainty (⨁◯◯◯): we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. *The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
is mentioned in the article that 'similar results were obtained when the incidence rate was calculated as events per person-years' (however, these data were not shown).
As the development of inhibitors against FVIII is dependent on exposure to FVIII, and therefore follow-up time, the reporting of incidence rates is preferred over proportions of patients with inhibitors. In addition, conventional data pooling methods (such as the one used in the aforementioned meta-analysis) are based on large sample approximations, which produce biased estimates when applied to studies with very low event rates [56] , as is the case for inhibitor development in PTPs.
Study strengths and limitations
Study strengths The last review included studies up to January 2013. Of the 41 cohorts included in this analysis, 14 cohorts were published after this date. In contrast to previous reviews, the incidence rate was used as the main study outcome instead of the cumulative incidence or the hazard rate. Because the study duration was not identical across studies, we chose not to use the cumulative inhibitor incidence as the main outcome. Furthermore, because most studies did not report the follow-up time of non-inhibitor patients, we also chose not use the hazard rate as the main outcome. Unlike earlier reviews, we also directly compared the pooled inhibitor incidence rates of all major rFVIII products with each other.
Standard meta-analysis methods (e.g. the DerSimonian-Laird random-effects method) can give biased results when applied inappropriately. First, the effect estimate and standard error of each study are usually correlated. Second, pooling studies with zero events leads to computational errors; this is often avoided by applying a continuity correction. Finally, the within-study distribution of the effect estimate is assumed to be normal, but this assumption is often violated when the event rate is very low. The meta-analysis model used in this review, a random intercept Poisson regression model, avoids the aforementioned problems [16] .
Limitations -random variation The pooled results have to be interpreted with caution, owing to the low number of inhibitors within each product type, which gives rise to significant random variation, as indicated by the broad CIs. Furthermore, hemophilia severity, follow-up time and the prior number of days of exposure to FVIII were not accurately reported in several studies (Table S1) , so these studies were excluded (after attempts to retrieve this information by contacting the corresponding authors). Because of the low event rate overall, the absence of these studies in the metaanalysis may have significantly impacted on our results.
Limitations -confounding As no comparative studies were found, we could only compare single-arm trials in our analysis of inhibitor formation by product type. Owing to differences in the distribution of genetic/treatment-related risk factors, comparing single-arm trials may be misleading.
Many studies also included patients with moderately severe disease (the exact proportion varied per study). If patients with moderately severe disease are at a significantly lower risk of inhibitor formation, then this could have confounded our results.
Patients receiving prophylactic treatment are exposed to more units of FVIII over a given time period than those receiving on-demand treatment, and are therefore at higher risk of inhibitor formation. Correcting for this problem by using days of exposure to FVIII instead of person-years as the unit of time in the main analysis was not feasible, owing to the low number of studies that accurately reported the total number of days of exposure to FVIII.
Adjustment for other potential confounders, such as F8 genotype, ethnicity, family history, and surgery, was not possible, owing to incomplete reporting (Table S3) . Overall, there is a moderate chance of confounding, mainly because of variables that may have influenced the physician's choice of rFVIII product (F8 genotype and family history of inhibitors).
Limitations -bias The cut-off level and screening frequency of the inhibitor assays, which could have influenced the reported number of low-titer inhibitors, varied across studies. This could have introduced misclassification bias, and consequently overestimation or underestimation of inhibitor incidence rates. Patients in market approval studies undergo more intensive screening for inhibitors. (Transient) low-titer inhibitors that were not detected before the study or at study baseline may be detected after inclusion. Because of this, newer products for which data are mainly available from market approval studies may seem more immunogenic than older products that have also been evaluated in post-approval studies.
Over time, the screening intensity has increased, possibly leading to increased detection of low-titer inhibitors in newer studies. However, the screening intensity was slightly higher among older products (Kogenate/Helixate and Refacto) than among newer products (Kogenate FS/ Helixate NexGen and Refacto AF) ( Table 1 ). This observation is in line with our results, as Kogenate/ Helixate and Refacto were also the most immunogenic products in our analysis. Correcting for this problem by analyzing only high-titer inhibitors was not feasible, owing to the very low number of high-titer inhibitors overall.
In addition, there could have been some overlap between five studies (which evaluated Advate, Kogenate FS/Helixate NexGen, or Refacto AF) and the EUHASS registry [23] (Table 1) . Double counting could have led to overestimation or underestimation of inhibitor incidence rates, and overly narrow CIs. Because Advate was used as the reference product, reported IRRs for all product types would also be biased. Overall, double counting could have influenced the main results.
Many patients were treated with a different FVIII product before study inclusion (especially in market approval trials). Consequently, increased immunogenicity resulting from product switching could have biased the results. However, there have been several national product switches, and there was no evidence of increased immunogenicity [57] .
Biological explanation of a causal effect
Several differences between rFVIII products could explain the reported results. Second-generation and third-generation full-length rFVIII products vary slightly in their FVIII amino acid sequences. Furthermore, differences in product formulation, such as culture conditions and stabilizing agents, could also be relevant. Finally, the type of cell culture used for production, such as CHO cells, BHK cells, or, more recently, HEK293 cells, leads to rFVIII products with different post-translational modifications that may influence immunogenic potential [11] .
Implications of these results for future research
Comparing single-arm trials may be misleading, owing to bias and confounding. Single-arm trials are useful for identifying extremely immunogenic products, but less suitable for detecting smaller effects (e.g. the difference in inhibitor risk found in the studies by Peyvandi et al. [2] and Gouw et al. [58] ). Nevertheless, these studies could be used more effectively if a standardized data reporting system was used. This system should include all relevant variables, such as known genetic/treatmentrelated confounders. [59] Finally, future research should focus on using study designs that are appropriate for evaluating rare outcomes (i.e. case-control studies).
Conclusion
These results suggest that some products may be associated with increased immunogenicity. However, these findings should be interpreted with caution, as both the low incidence of inhibitors in PTPs and the differences in study design may cause significant variation in estimates of risk.
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